Condition: Cardiovascular Autonomic Neuropathy · Type 2 Diabetes · Diabetic Neuropathies · Sponsor: Peter Rossing
Diabetic neuropathy is a serious and common complication of diabetes that currently has no cure. One form of this condition is cardiovascular autonomic neuropathy (CAN), which affects about 20% of people with diabetes-an estimated 100 million people worldwide. CAN is a significant risk factor for death and health problems like heart disease and kidney damage, and may contribute to the high rates of cardiovascular-related deaths in people with diabetes. This study is a double-blind, randomized, placebo-controlled, two-center trial. The study aims to test whether finerenone can treat cardiovascular autonomic neuropathy in patients with type 2 diabetes. The trial will evaluate the effects of 78 weeks of treatment with finerenone or a placebo, assigned randomly in a 1:1 ratio, on early-stage cardiovascular autonomic neuropathy. The trial will include 100 participants with type 2 diabetes. Additionally, the study will investigate how the treatment impacts other types of neuropathy and related pathological mechanisms.
This description comes directly from the study's public registry record.
Peter Rossing, Professor, MD · +4530913383 · peter.rossing@regionh.dk
Christian Stevns Hansen, Ph.D, MD · +4561671618 · christian.stevns.hansen@regionh.dk
Always discuss trial participation with your own doctor first.
| Steno Diabetes Center Northern Denmark | Gistrup, Denmark | Recruiting |
| Steno Diabetes Center Copenhagen | Herlev, Denmark | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06906081